Home » Blog » Drug Formulary, Quality Reporting, Prescription Database, Pharmaceutical Companies Sold, and Drug Rebates

Drug Formulary, Quality Reporting, Prescription Database, Pharmaceutical Companies Sold, and Drug Rebates


IP Blog | Dave Melin | January 22, 2017

BioBlog Weekly oncologyIn this week’s BioBlog we look at a new drug formulary, the new MACRA fact sheets, and the development of a universal prescription database. Also in the news the sale of pharmaceutical companies, and drug rebates that health plan providers receive.

New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials

This week The National Cancer Institute launched a new drug formulary that will give faster access to agents in clinical trials.

MACRA Fact Sheets Help Oncology Practices Prepare for Successful Quality Reporting

ASCO has developed a tool kit to help guide providers through the MACRA implementation process.

Novartis, Pfizer Join With Big Biopharma Peers to Create Tech Standards That Streamline How HCPs Access Info

More pharmaceutical companies are joining in the initiative to create one database for all drug information.

FiercePharmaAsia: Takeda’s $5.2B Deal for Ariad and $125M with Maverick, Valeant’s $820M Dendreon Sell to Chinese Company, and More

There has been a lot of movement recently in the sale of several drug companies.

Under Scrutiny, Health Plans Explain Drug Rebates, How Strategies Work in HDHPs

This article discusses the recent uproar due to consumers being unhappy that their health plans receive a rebate on prescriptions, while they still pay full price.


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *